Mersana Therapeutics Inc (MRSN) - Total Assets
Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) holds total assets worth $62.69 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mersana Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how Mersana Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see MRSN market cap for the company's overall valuation and market capitalisation.
Mersana Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Mersana Therapeutics Inc's total assets of $62.69 Million consist of 94.6% current assets and 5.4% non-current assets. Review debt load of Mersana Therapeutics Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Mersana Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Mersana Therapeutics Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mersana Therapeutics Inc's current assets represent 94.6% of total assets in 2024, an increase from 88.5% in 2015.
- Cash Position: Cash and equivalents constituted 74.5% of total assets in 2024, down from 80.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Mersana Therapeutics Inc Competitors by Total Assets
Key competitors of Mersana Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Mersana Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.39 | 2.35 | 8.62 |
| Quick Ratio | 1.39 | 2.35 | 8.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.72 Million | $92.26 Million | $228.58 Million |
Mersana Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Mersana Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 32.03 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | -36.0% |
| Total Assets | $144.66 Million |
| Market Capitalization | $145.36 Million USD |
Valuation Analysis
Near Book Valuation: The market values Mersana Therapeutics Inc's assets close to their book value (1.00x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Mersana Therapeutics Inc's assets decreased by 36.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mersana Therapeutics Inc (2015–2024)
The table below shows the annual total assets of Mersana Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $144.66 Million | -36.01% |
| 2023-12-31 | $226.06 Million | -32.39% |
| 2022-12-31 | $334.34 Million | +62.21% |
| 2021-12-31 | $206.11 Million | -24.61% |
| 2020-12-31 | $273.40 Million | +154.23% |
| 2019-12-31 | $107.54 Million | +36.99% |
| 2018-12-31 | $78.50 Million | -39.94% |
| 2017-12-31 | $130.72 Million | +24.39% |
| 2016-12-31 | $105.09 Million | +629.32% |
| 2015-12-31 | $14.41 Million | -- |
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more